ArticleMolecular medicine (Cambridge, Mass.)2025
Characterization of Ultra-Short plasma Cell-Free DNA in maternal blood and its preliminary potential as a screening marker for preeclampsia.
Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Reappraising the topology of cell-free fetal DNA in maternal blood toward improved prenatal genetic diagnostics.Science advances · 2026Review
- Cell-Based and Cell-Free Non-Invasive Prenatal Analysis of Preeclampsia: An Updated Review of Liquid Biopsy.Biomedicines · 2026Review
- Holistic determination of ends of cfDNA molecules.Cell genomics · 2026Article
- Epigenetic Regulation of Imprinted Genes in the Neurodevelopment of Offspring Born to Women with Preeclampsia: A Review.International journal of women's health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundCell-free DNA (cfDNA) in maternal blood is the foundation for non-invasive prenatal screening (NIPS). Recently, ultra-short cfDNA fragments, ranging from 30 to 70 base pairs (bp), have been identified and show promise in cancer diagnostics. However, the characteristics of ultra-short cfDNA in maternal blood during pregnancy remain unexplored. This study aims to characterize these fragments in pregnancy and evaluate their potential as biomarkers for preeclampsia.
methodsUltra-short cfDNA was isolated from the plasma of pregnant and non-pregnant women, and next-generation sequencing (NGS) was constructed. We performed deep sequencing to profile ultra-short cfDNA during pregnancy, including a cohort of women with preeclampsia, to identify distinct ultra-short peaks. These features were used to build a diagnostic model, which was validated in a separate testing cohort.
resultsSequencing data revealed that ultra-short cfDNA in maternal blood primarily originates from accessible open chromatin regions in blood and placental cells. A significant proportion of these fragments exhibited potential G-quadruplex (G4) motifs on the antisense strand. Significant differences in ultra-short cfDNA features were observed between women with preeclampsia and healthy controls. Based on these features, the diagnostic model achieved an area under the curve (AUC) of 0.90 in the training cohort and 0.86 in the test cohort.
conclusionsThis study comprehensively characterizes ultra-short cfDNA in maternal blood and suggests its preliminary potential as a diagnostic marker for early preeclampsia detection.
trial registrationRetrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.